



OMB#: 0925-0648 Exp Date: 7/2027

Public reporting burden for this collection of information is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0648). Do not return the completed form to this address.

Thank you for attending the 2024 CPTN Virtual Trainee and Scholar Orientation! Please take a few minutes to provide your feedback so we can improve future meetings.

Responses are anonymous. If you would like a response, please contact us at bpca@infinityconferences.com.

All questions are optional, and you may exit the survey at any time.

Please click Next to begin the survey.






GENERAL EXPERIENCE

On a scale of 1 to 5,	with 5 being the	best, how would	you rate the	orientation
experience?				

1 (Poor)	2	3		4	5 (Excellent)			
Additional Comment	CS							
	On a scale of 1 to 5, with 5 being the best, how would you rate the quality of support received during the orientation?							
1 (Poor)	2	3	4	5 (Excellent)	N/A			
Additional Comments								
				6				

Best Pharmaceuticals for Children Act





AGENDA FEEDBACK

On a scale of 1 to 5, with 5 being the best, please rate the following sessions:

1 (Poor)	2	3	4	5 (Excellent)
ditional Commen	ts			
SSION II: Navig	ating the NIH			
_	_	H Program Officers (Popkin)	; Working with NIH Scier	ntific Review Officers
Jargon and Acronyms			,	
bins); Mock Study Sect	cion Review]	3	4	5 (Excellent)
			4	5 (Excellent)
bins); Mock Study Sect 1 (Poor)	cion Review]		4	5 (Excellent)
bins); Mock Study Sect 1 (Poor)	cion Review]		4	5 (Excellent)
bins); Mock Study Sect 1 (Poor)	cion Review]		4	5 (Excellent)
bins); Mock Study Sect 1 (Poor)	cion Review]		4	5 (Excellent)
bins); Mock Study Sect 1 (Poor)	cion Review]		4	5 (Excellent)
bins); Mock Study Sect 1 (Poor)	cion Review]		4	5 (Excellent)
bins); Mock Study Sect 1 (Poor) Jitional Commen	tion Review] 2 ts	3	4	5 (Excellent)
bins); Mock Study Sect 1 (Poor) Hitional Commen	tion Review] 2 Its Its Ing the Most of You	3 Ir Training	*	*
bins); Mock Study Sect 1 (Poor) Hitional Commen	tion Review] 2 Its Its Its Most of Youth a Mentor (Taylor-Zapata	3	*	*
bins); Mock Study Sect 1 (Poor) Hitional Commen	tion Review] 2 Its Its Its Most of Youth a Mentor (Taylor-Zapata	3 Ir Training	*	*
bins); Mock Study Sect 1 (Poor) litional Commen SSION III: Makir tifying and Working wireer Development Opp	tion Review] 2 Its Its Its Its A mentor (Taylor-Zapata ortunities)	3 Ir Training ; Planning Your Training & C	areer Development Time	eline (Girardi); Novel Tra
bins); Mock Study Sect 1 (Poor) Hitional Commen	tion Review] 2 Its Its Its Most of Youth a Mentor (Taylor-Zapata	3 Ir Training	*	*

1 (Poor)	2	3	4	5 (Excellent)
itional Comments	S			

Best Pharmaceuticals for Children Act



of Child Health and Human Development

GENERAL FEEDBACK

On a scale of 1 to 5, what is your overall rating of the 2024 Clinical Pharmacology Training Network (CPTN) Trainee & Scholar Orientation?

1 (Poor)	2	3	4	5 (Excellent)
Additional Comments				
Do you feel better proheard at the orientat		orted in your trainin	g career as a resu	lt of what you
			a de	
Are there other topic weren't covered during			new trainees to h	near about that
Please provide any accontent, or logistical		ments regarding th	e hybrid meeting	format, agenda
			la de	

Thank you for your feedback! As a reminder, all responses are anonymous. If you would like a response to your comments, please reach out via email to bpca@infinityconferences.com.